- Bonesupport Holding reported third quarter 2026 sales of SEK 408.83 million and net income of SEK 92.36 million, with basic earnings per share from continuing operations at SEK 1.41.
- The company also completed a share buyback program totaling 641,320 shares for SEK 142.6 million, which modestly reduced the share count and increased the relative weight of each remaining share in future earnings.
- We will look at how Bonesupport Holding's investment narrative is shaped by this strong earnings print and completed buyback.
Bonesupport Holding Investment Narrative Recap
For a shareholder in Bonesupport Holding, the core belief is that its CERAMENT portfolio can keep gaining traction in key markets while pricing and reimbursement support remain intact. The latest quarter showed higher sales and earnings, which helps underpin that view. The main short term swing factor still sits in execution around U.S. adoption and reimbursement, while currency moves and selling expenses continue to hang over margins.
The completed buyback, combined with rising earnings per share, may slightly tighten the link between operational progress and per share results, but it does not change the central near term catalyst. The biggest risk remains pressure on reimbursement schemes and healthcare system capacity in Europe. Those factors could quickly affect volume growth even if product demand stays healthy.
The third quarter 2026 earnings release is the announcement that matters most for this news. It provided fresh evidence on how Bonesupport Holding is converting CERAMENT usage into SEK 408.83 million of quarterly sales and SEK 92.36 million of net income, plus SEK 1.41 in basic earnings per share from continuing operations.
That same update framed the current catalyst and risk picture more clearly. Stronger nine month earnings of SEK 227.62 million and SEK 3.47 in basic earnings per share support the case that operating leverage is working, while also highlighting that any hit from currency shifts, reimbursement changes or high selling costs would show up quickly in these headline figures.
Bonesupport Holding's current consensus outlook points to revenues of SEK 2.8 billion and earnings of SEK 854.7 million by 2029, based on analysts assuming 32.7% yearly revenue growth. That path implies earnings rising by about SEK 669.6 million from SEK 185.1 million today to the 2029 forecast level.
Uncover why Bonesupport Holding's fair value indicates a 12% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
One alternate storyline around Bonesupport Holding focuses on slower adoption inside those 140 plus U.S. Level 1 trauma centers. The most cautious analysts were only pencilling in around SEK 2.5b of revenue and SEK 738.2m of earnings by 2029 before this latest earnings and buyback news, so their view could shift as fresh data lands.
Explore 3 other Bonesupport Holding fair value estimates, including one that suggests as much as 9% downside from the current price.
Form Your Own Verdict
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Bonesupport Holding research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Bonesupport Holding. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bonesupport Holding's overall financial health at a glance.
Looking for more investment ideas beyond Bonesupport Holding?
Once you have a view on Bonesupport Holding, it can help to widen the lens and compare it with other businesses that fit different risk, income, and quality profiles using the Simply Wall St Screener.
- For investors who want potential mispricing with quality still intact, start with a curated set of 192 high quality undervalued stocks that pair stronger fundamentals with more modest expectations baked into prices.
- If capital preservation sits higher on your list, consider a group of 221 resilient stocks with low risk scores that screen well on volatility and balance sheet resilience.
- For those who care most about financial strength and durability, focus on the list of solid balance sheet and fundamentals (204 results) which can help surface businesses with cleaner debt profiles and sturdier fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com